The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice

Journal of Immunology

Volumn 164, Issue 5, 2000, Pages 2354-2361

  Bullock, Timothy N J ^a   Colella, Teresa A ^a   Engelhard, Victor H ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

EID: 0034162484     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.5.2354     Document Type: Article

References (56)

1. Rosenberg, S. A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281.
2. Fernandez, N., M. T. Duffour, M. Perricaudet, M. T. Lotze, T. Tursz, and L. Zitvogel. 1998. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines: principles and future prospects. Cytokines Cell. Mol. Ther. 4:53.
3. Robbins, P. F., and Y. Kawakami. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628.
4. Rosenberg, S. A. 1996. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu. Rev. Med. 47:481.
5. Engelhard, V. H. 1996. Direct identification of tumor-associated peptide antigens. Springer Semin. Immunopathol. 18:171.
6. Rosenberg, S. A., Y. Kawakami, P. F. Robbins, and R. Wang. 1996. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv. Cancer Res. 70:145.
7. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
8. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716.
9. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwuod, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
10. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
11. Nestle, F. O., S. Alijagic, M. Gilliel, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
12. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
13. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
14. Van der Burg, S. H., M. J. Visseren, R. M. Brandt, W. M. Kast, and C. J. Melief. 1996. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156:3308.
15. Deng, Y., J. W. Yewdell, L. C. Eisenlohr, and J. R. Bennink. 1997. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158:1507.
16. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.
17. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. DeLeo, and M. T. Lotze, 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297.
18. Kaplan, J. M., Q. Yu, S. T. Piraino, S. E. Pennington, S. Shankara, L. A. Woodworth, and B. L. Roberts. 1999. Induction of anti-tumor immunity using dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163:699.
19. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
20. Timmerman, J. M., and R. Levy. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:507.
21. Bronte, V., M. W. Carroll, T. J. Goletz, M. Wang, W. W. Overwijk, F. Marincola, S. A. Rosenberg, B. Moss, and N. P. Restifo. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA 94:3183.
22. Nair, S. K., S. Hull, D. Coleman, E. Gilboa, H. K. Lyerly, and M. A. Morse. 1999. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer 82:121.
23. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
24. Porgador, A., and E. Gilboa. 1995. Bore marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
25. Skipper, J. C. A., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. Slingluff, T. Boon, et al. 1996. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J. Exp. Med. 183:527.
26. Slingluff, C. L., Jr., A. L. Cox, R. A. Henderson, D. F. Hunt, and V. H. Engelhard. 1993. Recognition of human melanoma cells by HLA-A2.1-restricted CTL is mediated by at least six shared peptide epitopes. J. Immunol. 150:2955.
27. Newherg, M. H., D. H. Smith, S. B. Haertel, D. R. Vining, E. Lacy, and V. H. Engelhard. 1996. Importance of MHC class I α2 and α3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 156:2473.
28. Mosse, C. A., L. Meadows, C. J. Luckey, D. J. Kittlesen, E. L. Huczko, C. L. Slingluff, Jr., J. Shabanowitz, D. F. Hunt, and V. H. Engelhard. 1998. The class I antigen processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187:37.
29. Man, S., M. H. Newberg, V. L. Crotzer, C. J. Luckey, N. S. Williams, Y. Chen, E. L. Huczko, J. P. Ridge, and V. H. Engelhard. 1995. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int. Immunol. 7:597.
30. Engelhard, V. H., E. Lacy, and J. P. Ridge. 1991. Influenza A specific, HLA-A2.1 restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the MI protein. J. Immunol. 146:1226.
31. Shirai, M., T. Arichi, M. Nishioka, T. Nomura, K. Ikeda, K. Kawanishi, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1995. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.I. J. Immunol. 154:2733.
32. Chen, Y., J. Sidney, S. Southwood, A. L. Cox, K. Sagaguchi, R. Henderson, E. Appella, D. F. Hunt, A. Seite, and V. H. Engelhard. 1994. Naturally processed peptides longer than nine amino acid residues bind to the class I molecule HLA-A2.1 with high affinity and in different conformations. J. Immunol. 152:2874.
33. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
34. Wang, W., S. Man, P. H. Gulden, D. F. Hunt, and V. H. Engelhard. 1998. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides. J. Immunol. 160:1091.
35. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
36. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanomareactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
37. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750.
38. Irvine, K. R., M. R. Parkhurst, E. P. Shulman, J. P. Tupesis, M. Custer, C. E. Touloukian, P. F. Robbins, A. G. Yafal, P. Greenhalgh, R. P. Sutmuller, et al. 1999. Recombinant virus vaccination against "self" antigens using anchorfixed immunogens. Cancer Res. 59:2536.
39. Vifiello, A., D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chestnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007.
40. 2m double knockout mice. J. Exp. Med. 185:2043.
41. Morse, M. A., H. K. Lyerly, E. Gilboa, E. Thomas, and S. K. Nair. 1998. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res 58:2965.
42. Lanzavecchia, A. 1996. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8:348.
43. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class 11 complexes on dendritic cells. Nature 388:782.
44. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5:774.
45. Alexander-Miller, M. A., M. A. Derby, A. Sarin, P. A. Henkart, and J. A. Berzofsky. 1998. Supraoptimal peptide-major histocompatibility complex causes a decrease in bcl-2 levels and allows tumor necrosis factor α receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 188:1391.
46. Wherry, E. J., K. A. Puorro, A. Porgador, and L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of antigen are attained. J. Immunol. 163:3735.
47. Vijh, S., I. Pilip, and E. G. Pamer. 1998. Effect of antigen-processing efficiency on in vivo T cell response magnitudes. J. Immunol. 160:3971.
48. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
49. Kurts, C., J. F. Miller, R. M. Subramaniam, F. R. Carbone, and W. R. Heath. 1998. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188:409.
50. Bakker, A. B., S. H. van der Burg, R. J. Huijbens, J. W. Drijfhout, C. J. Melief, G. J. Adema, and C. G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer 70:302.
51. Men, Y., I. Miconnet, D. Valmori, D. Rimoldi, J. C. Cerottini, and P. Romero. 1999. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J. Immunol. 162:3566.
52. + T cells with enhanced functional characteristics: implication for more effective immunotherapy Cancer Res. 59:301.
53. Hemmer, B., I. Stefanova, M. Vergelli, R. N. Germain, and R. Martin. 1998. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J. Immunol. 160:5807.
54. + T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res. 58:2433.
55. 209-217-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol. 162:1749.
56. + T cell tolerance to peripherally expressed antigens. J. Immunol. 163:723.